NEW YORK, July 20, 2017 (GLOBE NEWSWIRE) -- Calyxt (Nasdaq:CLXT), a consumer-centric, food- and agriculture-focused company, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
Photos accompanying this announcement are available at
Calyxt seeks to bridge the divide between evolving consumer preferences and the historical approach by the large legacy companies in the agriculture supply chain. By combining its leading gene editing technology and technical expertise with its innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver healthier specialty food ingredients for consumers and agriculturally advantageous crop traits to farmers.
“As more and more food companies are looking for specialty ingredients that can help them to satisfy customers’ evolving needs and desire to lead healthier lifestyles, Calyxt is perfectly positioned to be an industry leader with the emergence of gene editing as a truly game-changing technology in the food space,” said Federico Tripodi, CEO, Calyxt. “Coupled with our innovative commercial strategy, this will allow Calyxt to meet the needs of today’s consumer preferences – all of the while helping to shape the landscape for the future of food as we know it.”
“Calyxt believes that the precision, specificity, cost-effectiveness and development speed of the company’s gene editing technologies will enable it to provide meaningful disruption to the food and agriculture industries. We are proud to welcome Calyxt to the Nasdaq family of innovators,” said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. By combining its leading gene-editing technology and technical expertise with its innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance, for farmers. Calyxt is located in Minneapolis-St. Paul, Minn., and is a wholly owned subsidiary of Cellectis.
For further information please visit our website: www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
Talking about gene editing? We do it.
TALEN® is a registered trademark owned by the Cellectis Group.
- NDAQG -
Media Relations Contacts: Stephanie Lowenthal (646) 441-5073 Stephanie.Lowenthal@nasdaq.com Emily Pan (646) 441-5120 email@example.com Caitlin Kasunich / Nick Opich KCSA Strategic Communications 212.896.1241 / 212.896.1206 firstname.lastname@example.org / email@example.com